where was glp 1 discovered Gila monster venom… and weight loss? 🦎 It sounds wild, but it's true. GLP-1 medications were inspired by a hormone first in the saliva of a Gila monster. On this week's The Discovery of Glucagon-Like Peptide

(34) However, the focus of this review was primarily on the cardiovascular and renal benefits of these therapies, with little to no emphasis on musculoskeletal outcomes

Ensure that people stopping medicines for weight management: Receive feedback and monitoring at regular intervals for a minimum of 1 year so they can get help if they are not maintaining changes Have well rehearsed action plans (such as 'ifthen' plans) that they can easily put into practice if they are not maintaining changes Have thought about how they can make changes to their own immediate physical environment to prevent weight regain Have the social support they need to maintain changes Are helped to develop routines that support the new behaviour Are offered a range of options for follow-up sessions after an intervention active phase Ensure that weight management interventions encourage people to make lifelong behavioural changes and prevent future weight gain, by: Fostering independence and self-management (including self-monitoring) Encouraging dietary behaviours that support weight maintenance and can be sustained in the long term Emphasising the wider benefits of keeping up levels of physical activity over the long term Discussing strategies to overcome any difficulties in maintaining behavioural changes Encouraging family-based changes Discussing sources of ongoing support once the intervention or referral period has ended Read more here American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society While specific nutritional and other behaviours that contribute to weight maintenance after stopping GLP-1 therapy have not been rigorously studied, a joint advisory from several leading American medical societies highlights that other observational data can show general predictors for successful long term weight reduction

doi: 10.1111/dom.12247

The FDA authorized Eli Lillys drug as part of a new program aimed at cutting drug approval times, reviewing the application in in 50 days

Table 2 summarizes RCTs of dual and triple GLP1-RA use in T2DM